Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
WALD Stock Forecast 2026-2027
$1.73
Current Price
$229.59M
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to WALD Price Targets
+73.4%
To High Target of $3.00
+30.1%
To Median Target of $2.25
-7.5%
To Low Target of $1.60
WALD Price Momentum
0.0%
1 Week Change
+4.2%
1 Month Change
-24.8%
1 Year Change
-8.0%
Year-to-Date Change
-46.3%
From 52W High of $3.22
+140.3%
From 52W Low of $0.72
📊 TOP ANALYST CALLS
Did WALD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Waldencast is one of their latest high-conviction picks.
Latest WALD Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, WALD has a neutral consensus with a median price target of $2.25 (ranging from $1.60 to $3.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.73, the median forecast implies a 30.1% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Susan Anderson at Canaccord Genuity, projecting a 73.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
WALD Analyst Ratings
2
Buy
2
Hold
0
Sell
WALD Price Target Range
Low
$1.60
Average
$2.25
High
$3.00
Current: $1.73
Latest WALD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for WALD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 2, 2026 | Canaccord Genuity | Susan Anderson | Buy | Maintains | $3.00 |
| Mar 16, 2026 | Telsey Advisory Group | Market Perform | Maintains | $N/A | |
| Mar 16, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jan 14, 2026 | Jefferies | Sydney Wagner | Buy | Assumes | $2.00 |
| Nov 25, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 25, 2025 | Telsey Advisory Group | Market Perform | Downgrade | $N/A | |
| Aug 20, 2025 | Telsey Advisory Group | Outperform | Maintains | $N/A | |
| Aug 13, 2025 | Telsey Advisory Group | Outperform | Maintains | $N/A | |
| May 15, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 15, 2025 | Telsey Advisory Group | Outperform | Maintains | $N/A | |
| May 6, 2025 | Telsey Advisory Group | Outperform | Maintains | $N/A | |
| Apr 22, 2025 | Alliance Global Partners | Buy | Initiates | $N/A | |
| Mar 20, 2025 | Telsey Advisory Group | Outperform | Maintains | $N/A | |
| Mar 19, 2025 | DA Davidson | Buy | Maintains | $N/A | |
| Mar 19, 2025 | Telsey Advisory Group | Outperform | Maintains | $N/A | |
| Mar 11, 2025 | Telsey Advisory Group | Outperform | Maintains | $N/A | |
| Dec 16, 2024 | TD Cowen | Hold | Initiates | $N/A | |
| Dec 4, 2024 | DA Davidson | Buy | Maintains | $N/A | |
| Nov 22, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 22, 2024 | Telsey Advisory Group | Outperform | Maintains | $N/A |
Waldencast plc (WALD) Competitors
The following stocks are similar to Waldencast based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Waldencast plc (WALD) Financial Data
Valuation Metrics
Market Cap
$229.59M
Enterprise Value
$354.31M
P/E Ratio
N/A
PEG Ratio
-2.1x
Price/Sales
0.8x
Growth & Margins
Revenue Growth (YoY)
-1.7%
Gross Margin
N/A
Operating Margin
-22.5%
Net Margin
-84.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+14.9%
Current Ratio
1.7x
Debt/Equity
29.8x
ROE
-40.3%
ROA
-4.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Waldencast plc (WALD) Business Model
About Waldencast plc
What They Do
Invests in beauty and wellness companies.
Business Model
Waldencast plc builds a portfolio of high-growth businesses in the beauty and wellness sectors by investing in and nurturing emerging brands. The company generates revenue through its strategic investments, leveraging industry expertise and relationships to foster growth and innovation in its portfolio companies.
Additional Information
The company emphasizes sustainability and consumer-centric strategies, aligning with global trends towards conscious consumption. Waldencast collaborates with entrepreneurs and industry experts to scale businesses, often incorporating sustainable practices and innovative technology, positioning itself as a key player in driving growth and innovation in the beauty and wellness industries.
Company Information
Sector
Consumer Defensive
Industry
Household & Personal Products
Employees
367
CEO
Mr. Michel Brousset
Country
United Kingdom
IPO Year
2021
Website
www.waldencast.comWaldencast plc (WALD) Latest News & Analysis
Latest News
Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel
1 month ago
Quick Summary
Waldencast plc (NASDAQ: WALD) announced FDA approval for Obagi® saypha® ChIQ™ injectable HA gel, enhancing its Obagi Medical brand and supporting its strategy in advanced skincare and medical aesthetics.
Why It Matters
FDA approval of Obagi's new injectable product enhances Waldencast's market position and growth potential in the beauty sector, likely boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Waldencast plc (NASDAQ: WALD) has agreed to sell its Obagi Medical business to Bridgepoint for up to $460 million, aiming to strengthen its balance sheet and focus on Milk Makeup's growth.
Why It Matters
Waldencast's $460 million sale of Obagi Medical enhances its balance sheet and redirects focus to Milk Makeup, potentially driving future growth and improving investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum demonstrate positive results aimed at enhancing practice success.
Why It Matters
Positive data from ALOHA and NU-GEN™ could indicate strong product performance, potentially boosting sales and profitability for the company, influencing stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A multi-city pop-up event is launching to showcase advancements in skincare and longevity innovation to consumers.
Why It Matters
The launch of a multi-city pop-up for skincare and longevity innovation signals potential growth in a lucrative market, attracting consumer interest and possibly driving stock performance in related companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Obagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin*
2 months ago
Quick Summary
Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 offers mineral sun protection and skincare benefits, suitable for daily use.
Why It Matters
The launch of Sun Shield™ Mineral UV Barrier Protect SPF 40 indicates innovation in the skincare sector, potentially boosting sales and market share for the company, influencing stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Waldencast announces conclusion of SEC investigation
2 months ago
Quick Summary
Waldencast plc (NASDAQ: WALD) has been informed by the SEC that its investigation into financial restatements and internal control issues has concluded without recommending enforcement action.
Why It Matters
The SEC's decision not to recommend enforcement action alleviates regulatory risk for Waldencast, potentially boosting investor confidence and stabilizing its stock price.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About WALD Stock
What is Waldencast plc's (WALD) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, Waldencast plc (WALD) has a median price target of $2.25. The highest price target is $3.00 and the lowest is $1.60.
Is WALD stock a good investment in 2027?
According to current analyst ratings, WALD has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for WALD stock?
Wall Street analysts predict WALD stock could reach $2.25 in the next 12 months. This represents a 30.1% increase from the current price of $1.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Waldencast plc's business model?
Waldencast plc builds a portfolio of high-growth businesses in the beauty and wellness sectors by investing in and nurturing emerging brands. The company generates revenue through its strategic investments, leveraging industry expertise and relationships to foster growth and innovation in its portfolio companies.
What is the highest forecasted price for WALD Waldencast plc?
The highest price target for WALD is $3.00 from Susan Anderson at Canaccord Genuity, which represents a 73.4% increase from the current price of $1.73.
What is the lowest forecasted price for WALD Waldencast plc?
The lowest price target for WALD is $1.60 from at , which represents a -7.5% decrease from the current price of $1.73.
What is the overall WALD consensus from analysts for Waldencast plc?
The overall analyst consensus for WALD is neutral. Out of 6 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $2.25.
How accurate are WALD stock price projections?
Stock price projections, including those for Waldencast plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 3:08 AM UTC